Tomoko Udo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomoko Udo has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
Carlos M. Grilo
Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, Connecticut, USA
14 shared publications- Carlos M. Grilo
Department of Psychiatry Yale University School of Medicine New Haven Connecticut USA
7 shared publications Sherry A. McKee
Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
7 shared publications- Marney A. White
Department of Social and Behavioral Sciences Yale School of Public Health New Haven Connecticut USA
5 shared publications Rachel D. Barnes
Yale University School of Medicine, New Haven, CT, United States
5 shared publicationsRobin M. Masheb
Yale University School of Medicine, New Haven, CT, United States
5 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2950-2958
A comparative analysis of methodological practices used in capture–recapture population size estimation: opioid use disorder prevalence in New York State, 2020
Prevalence estimates for opioid use disorder (OUD) are essential for guiding investments in prevention and treatment. Previous estimates have been produced using modeling approaches including capture–recapture (CRC). Empirical evaluations of CRC are needed to assess population size impacts of methodological practices utilized. We linked administrative data sources including New York State (NYS) adults with OUD by indication between January 1 and December 31, 2020 and applied Bayesian CRC methods to evaluate how methodological practices impact OUD prevalence: (1) using sensitive vs specific case definition characteristics to identify OUD, (2) including vs excluding inferred referrals from emergency medical services to healthcare settings, and (3) including vs excluding overdose mortality as a source list. We estimated OUD prevalence overall and by demographic characteristics and treatment coverage with medications for OUD (MOUD). Across methodological scenarios, OUD prevalence estimates ranged from 4.6% to 9.9%. The largest estimate resulted from a model in which the more sensitive OUD case definition was applied, while the smallest resulted from a model using the more specific case definition. An estimated 4.2% of NYS adults had OUD in 2020, with 20% receiving MOUD. Findings demonstrate that CRC methodological decisions can meaningfully influence OUD prevalence estimates, with recommended methodological practices provided.
- 10 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (11) , 2950-2958
Open AccessA comparative analysis of methodological practices used in capture–recapture population size estimation: opioid use disorder prevalence in New York State, 2020
Prevalence estimates for opioid use disorder (OUD) are essential for guiding investments in prevention and treatment. Previous estimates have been produced using modeling approaches including capture–recapture (CRC). Empirical evaluations of CRC are needed to assess population size impacts of methodological practices utilized. We linked administrative data sources including New York State (NYS) adults with OUD by indication between January 1 and December 31, 2020 and applied Bayesian CRC methods to evaluate how methodological practices impact OUD prevalence: (1) using sensitive vs specific case definition characteristics to identify OUD, (2) including vs excluding inferred referrals from emergency medical services to healthcare settings, and (3) including vs excluding overdose mortality as a source list. We estimated OUD prevalence overall and by demographic characteristics and treatment coverage with medications for OUD (MOUD). Across methodological scenarios, OUD prevalence estimates ranged from 4.6% to 9.9%. The largest estimate resulted from a model in which the more sensitive OUD case definition was applied, while the smallest resulted from a model using the more specific case definition. An estimated 4.2% of NYS adults had OUD in 2020, with 20% receiving MOUD. Findings demonstrate that CRC methodological decisions can meaningfully influence OUD prevalence estimates, with recommended methodological practices provided.
- 9 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8) , e70208
Integrated Studies of Infectious Disease Elimination ( InSIDE ): Hepatitis C Antibody and RNA Status of Persons Who Inject Drugs in New York State, 2021–2023
Hepatitis C virus (HCV) infection disproportionately impacts people who inject drugs (PWID). Understanding the prevalence and correlates of current and lifetime HCV infection is necessary to inform prevention, testing and treatment efforts among PWID to reduce HCV burden and achieve HCV elimination targets in this population From June 2021–December 2023, 751 PWID were recruited from syringe service harm reduction programs (SSP) and by referral from communities around New York State (NYS). Participants completed web‐based surveys on risk factors and social determinants of health and were tested for HCV antibody and RNA to assess their current and lifetime HCV status (never infected, previously infected, or currently infected). Controlling for recruitment site as a fixed effect, a multivariate mixed logistic regression model was built to assess factors significantly associated with HCV status. Among PWID, 58% had a lifetime history of infection, and 29% were currently infected (50% among those with a lifetime history of infection). Daily/almost‐daily injection, opioid injection, homelessness, and experience of abscess (all past‐year) were significantly associated with current infection, as was younger age. Past‐year SSP utilization was associated with a lifetime history of infection. PWID are a priority population to achieve HCV elimination in NYS. Our findings show that HCV burden is high among PWID utilizing SSPs. Expanding access to HCV care and treatment in harm reduction service settings while also providing services to address social determinants of health may be an effective strategy to progress towards reducing the burden of HCV among PWID.
- 9 July 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (8) , e70208
Integrated Studies of Infectious Disease Elimination ( InSIDE ): Hepatitis C Antibody and RNA Status of Persons Who Inject Drugs in New York State, 2021–2023
Hepatitis C virus (HCV) infection disproportionately impacts people who inject drugs (PWID). Understanding the prevalence and correlates of current and lifetime HCV infection is necessary to inform prevention, testing and treatment efforts among PWID to reduce HCV burden and achieve HCV elimination targets in this population From June 2021–December 2023, 751 PWID were recruited from syringe service harm reduction programs (SSP) and by referral from communities around New York State (NYS). Participants completed web‐based surveys on risk factors and social determinants of health and were tested for HCV antibody and RNA to assess their current and lifetime HCV status (never infected, previously infected, or currently infected). Controlling for recruitment site as a fixed effect, a multivariate mixed logistic regression model was built to assess factors significantly associated with HCV status. Among PWID, 58% had a lifetime history of infection, and 29% were currently infected (50% among those with a lifetime history of infection). Daily/almost‐daily injection, opioid injection, homelessness, and experience of abscess (all past‐year) were significantly associated with current infection, as was younger age. Past‐year SSP utilization was associated with a lifetime history of infection. PWID are a priority population to achieve HCV elimination in NYS. Our findings show that HCV burden is high among PWID utilizing SSPs. Expanding access to HCV care and treatment in harm reduction service settings while also providing services to address social determinants of health may be an effective strategy to progress towards reducing the burden of HCV among PWID.
- Open Access
- 13 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e71-e78
Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States
A major barrier to hepatitis C virus (HCV) elimination in the United States (U.S.) is the lack of a point-of-care (POC) test to confirm the presence of HCV RNA. The purpose of this clinical trial was to evaluate the performance of the Xpert® HCV test at CLIA-waived sites in the U.S. Participants at risk and/or with signs/symptoms of HCV infection provided fingerstick blood that was tested on the Xpert® HCV test and venous blood tested using the cobas® HCV and Elecsys® Anti-HCV II tests. Fingerstick blood was collected at CLIA-waived sites by individuals self-trained on collection procedures. Participants (N=1279) were enrolled across 15 sites; 1015 (79.3%) were deemed eligible for further evaluation. Specimens from 985 (97.0%) participants with valid results for Xpert®, cobas and Elecsys were included in the performance analysis. The prevalence of HCV antibodies and HCV RNA was 34.6% and 12.4%, respectively. The Xpert® HCV test demonstrated a positive percent agreement (PPA) of 93.4% (95% CI: 87.6–96.6) and a negative percent agreement (NPA) of 99.8% (95% CI: 99.2–99.9) relative to the patient infected status (PIS). Data from this clinical trial showed that the Xpert® HCV test was sensitive, specific, and acceptable for use to detect HCV RNA in human EDTA fingerstick blood from individuals at risk and/or with signs/symptoms of HCV infection.
- 13 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e71-e78
Open AccessPerformance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States
A major barrier to hepatitis C virus (HCV) elimination in the United States (U.S.) is the lack of a point-of-care (POC) test to confirm the presence of HCV RNA. The purpose of this clinical trial was to evaluate the performance of the Xpert® HCV test at CLIA-waived sites in the U.S. Participants at risk and/or with signs/symptoms of HCV infection provided fingerstick blood that was tested on the Xpert® HCV test and venous blood tested using the cobas® HCV and Elecsys® Anti-HCV II tests. Fingerstick blood was collected at CLIA-waived sites by individuals self-trained on collection procedures. Participants (N=1279) were enrolled across 15 sites; 1015 (79.3%) were deemed eligible for further evaluation. Specimens from 985 (97.0%) participants with valid results for Xpert®, cobas and Elecsys were included in the performance analysis. The prevalence of HCV antibodies and HCV RNA was 34.6% and 12.4%, respectively. The Xpert® HCV test demonstrated a positive percent agreement (PPA) of 93.4% (95% CI: 87.6–96.6) and a negative percent agreement (NPA) of 99.8% (95% CI: 99.2–99.9) relative to the patient infected status (PIS). Data from this clinical trial showed that the Xpert® HCV test was sensitive, specific, and acceptable for use to detect HCV RNA in human EDTA fingerstick blood from individuals at risk and/or with signs/symptoms of HCV infection.
- 1 August 2024
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 75 (8) , 826-829
Opportunities and Challenges to Build Behavioral Health Crisis Capacity in Rural America
This column shares lessons learned from a 1-year pilot implementation of a crisis response program deploying crisis professionals to rural parts of Albany County, New York. The data (325 crisis interventions for 191 unique individuals, 57% of cases resolved on the scene) suggest that the program helps fill the crisis services gap in these communities. Police were present on 80% of cases. Educating police to build confidence in the program and providing clearer guidelines on the triage process for dispatchers may be important strategies to continue shifting crisis response duties from traditional first responders to crisis professionals.
- 1 August 2024
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 75 (8) , 826-829
Opportunities and Challenges to Build Behavioral Health Crisis Capacity in Rural America
This column shares lessons learned from a 1-year pilot implementation of a crisis response program deploying crisis professionals to rural parts of Albany County, New York. The data (325 crisis interventions for 191 unique individuals, 57% of cases resolved on the scene) suggest that the program helps fill the crisis services gap in these communities. Police were present on 80% of cases. Educating police to build confidence in the program and providing clearer guidelines on the triage process for dispatchers may be important strategies to continue shifting crisis response duties from traditional first responders to crisis professionals.
- 5 June 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 65 (5) , 827-834
Social Drivers of Mental Health: A U.S. Study Using Machine Learning
- 5 June 2023
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 65 (5) , 827-834
Social Drivers of Mental Health: A U.S. Study Using Machine Learning
- 18 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 35 (6) , 372-378
Epidemiology of eating disorders among US adults
Purpose of review: Public policy efforts for prevention of and intervention upon eating disorders is severely limited in the United States due to the paucity of population-based data. This review article summarizes findings regarding eating disorders based on the National Epidemiological Studies on Alcohol and Related Conditions, Third Wave. The studies reviewed provide the most recent epidemiological indicators of anorexia nervosa, bulimia nervosa, and binge-eating disorder (BED) in the United States and demonstrate the utility of population-based data for validating the generalizability of findings from clinical samples. Recent findings: Anorexia nervosa, bulimia nervosa, and BED are widely distributed across sociodemographic characteristics, with substantially elevated risks for a variety of serious psychiatric, medical, and functional impairments, including heighted suicidality over the lifespan. Sexual minorities and individuals with adverse childhood experiences may be particularly vulnerable. Yet, many adults with eating disorders do not seek help, particularly professional help. National Epidemiological Studies on Alcohol and Related Conditions, Third Wave studies also validated some important clinical observations (e.g., overvaluation of shape/weight and physical inactivity in BED, more severe anorexia nervosa with onset prior to 14 years old). Summary: More rigorous population-based studies are needed to further advocate for appropriate resources and policies for eating disorders in the United States.
- 18 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Psychiatry
- Vol. 35 (6) , 372-378
Epidemiology of eating disorders among US adults
Purpose of review: Public policy efforts for prevention of and intervention upon eating disorders is severely limited in the United States due to the paucity of population-based data. This review article summarizes findings regarding eating disorders based on the National Epidemiological Studies on Alcohol and Related Conditions, Third Wave. The studies reviewed provide the most recent epidemiological indicators of anorexia nervosa, bulimia nervosa, and binge-eating disorder (BED) in the United States and demonstrate the utility of population-based data for validating the generalizability of findings from clinical samples. Recent findings: Anorexia nervosa, bulimia nervosa, and BED are widely distributed across sociodemographic characteristics, with substantially elevated risks for a variety of serious psychiatric, medical, and functional impairments, including heighted suicidality over the lifespan. Sexual minorities and individuals with adverse childhood experiences may be particularly vulnerable. Yet, many adults with eating disorders do not seek help, particularly professional help. National Epidemiological Studies on Alcohol and Related Conditions, Third Wave studies also validated some important clinical observations (e.g., overvaluation of shape/weight and physical inactivity in BED, more severe anorexia nervosa with onset prior to 14 years old). Summary: More rigorous population-based studies are needed to further advocate for appropriate resources and policies for eating disorders in the United States.
- Open Access
- 25 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0268978
Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State
Background: Persons living with diagnosed HIV (PLWDH) are at increased risk for severe illness due to COVID-19. The degree to which this due to HIV infection, comorbidities, or other factors remains unclear.Methods: We conducted a retrospective matched cohort study of individuals hospitalized with COVID-19 in New York State between March and June 2020, during the first wave of the pandemic, to compare outcomes among 853 PLWDH and 1,621 persons without diagnosed HIV (controls). We reviewed medical records to compare sociodemographic and clinical characteristics at admission, comorbidities, and clinical outcomes between PLWDH and controls. HIV-related characteristics were evaluated among PLWDH.Results: PLWDH were significantly more likely to have cardiovascular (matched prevalence-ratio [mPR], 1.22 [95% CI, 1.07–1.40]), chronic liver (mPR, 6.71 [95% CI, 4.75–9.48]), chronic lung (mPR, 1.76 [95% CI, 1.40–2.21]), and renal diseases (mPR, 1.77 [95% CI, 1.50–2.09]). PLWDH were less likely to have elevated inflammatory markers upon hospitalization. Relative to controls, PLWDH were 15% less likely to require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) and 15% less likely to require admission to the intensive care unit. No significant differences were found in in-hospital mortality. PLWDH on tenofovir-containing regimens were significantly less likely to require mechanical ventilation or ECMO (risk-ratio [RR], 0.73 [95% CI, 0.55–0.96]) and to die (RR, 0.74 [95% CI, 0.57–0.96]) than PLWDH on non-tenofovir-containing regimens.Conclusions: While hospitalized PLWDH and controls had similar likelihood of in-hospital death, chronic disease profiles and degree of inflammation upon hospitalization differed. This may signal different mechanisms leading to severe COVID-19.
- 25 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0268978
Open AccessFactors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State
Background: Persons living with diagnosed HIV (PLWDH) are at increased risk for severe illness due to COVID-19. The degree to which this due to HIV infection, comorbidities, or other factors remains unclear.Methods: We conducted a retrospective matched cohort study of individuals hospitalized with COVID-19 in New York State between March and June 2020, during the first wave of the pandemic, to compare outcomes among 853 PLWDH and 1,621 persons without diagnosed HIV (controls). We reviewed medical records to compare sociodemographic and clinical characteristics at admission, comorbidities, and clinical outcomes between PLWDH and controls. HIV-related characteristics were evaluated among PLWDH.Results: PLWDH were significantly more likely to have cardiovascular (matched prevalence-ratio [mPR], 1.22 [95% CI, 1.07–1.40]), chronic liver (mPR, 6.71 [95% CI, 4.75–9.48]), chronic lung (mPR, 1.76 [95% CI, 1.40–2.21]), and renal diseases (mPR, 1.77 [95% CI, 1.50–2.09]). PLWDH were less likely to have elevated inflammatory markers upon hospitalization. Relative to controls, PLWDH were 15% less likely to require mechanical ventilation or extracorporeal membrane oxygenation (ECMO) and 15% less likely to require admission to the intensive care unit. No significant differences were found in in-hospital mortality. PLWDH on tenofovir-containing regimens were significantly less likely to require mechanical ventilation or ECMO (risk-ratio [RR], 0.73 [95% CI, 0.55–0.96]) and to die (RR, 0.74 [95% CI, 0.57–0.96]) than PLWDH on non-tenofovir-containing regimens.Conclusions: While hospitalized PLWDH and controls had similar likelihood of in-hospital death, chronic disease profiles and degree of inflammation upon hospitalization differed. This may signal different mechanisms leading to severe COVID-19.
- 14 July 2021
- Published by Wiley in International Journal of Eating Disorders
- Vol. 54 (9) , 1632-1640
Examining the significance of age of onset in persons with lifetime anorexia nervosa: Comparing child, adolescent, and emerging adult onsets in nationally representative U.S. study
Objective: This study compared sociodemographic and clinical profiles of adult patients with lifetime DSM‐5‐defined anorexia nervosa (AN) categorized by age‐of‐onset using data from U.S. national sample of adults.Method: Study included 216 participants from Third National Epidemiological Survey Alcohol and Related Conditions (NESARC‐III) who met criteria for lifetime AN based on structured diagnostic interviews (AUDADIS‐5) with age‐of‐onset prior to age 25. Of the 216 participants, 30 were categorized as child‐onset (SE = 2.04; child‐onset), 39.6% (SE = 2.69; adolescent‐onset), and 48.6% (SE = 2.67; emerging‐adult). Child‐onset group reported more frequent adverse childhood experiences (ACEs), lowest BMI, longest episode‐duration, was least likely to attend college, and had highest rate of lifetime psychiatric comorbidity. Child‐onset group had earliest age of help‐seeking and were most likely to have been hospitalized. Group differences persisted in analyses adjusting for sociodemographic characteristics and duration of AN episode.Discussion: Our findings, based on a nationally representative sample of U.S. adults with lifetime diagnoses of AN, suggest that those with child‐onset had more severe AN, greater life difficulties, and greater lifetime psychiatric comorbidity. Findings emphasize the importance of earlier recognition and rapid referral to effective treatments.
- 14 July 2021
- Published by Wiley in International Journal of Eating Disorders
- Vol. 54 (9) , 1632-1640
Examining the significance of age of onset in persons with lifetime anorexia nervosa: Comparing child, adolescent, and emerging adult onsets in nationally representative U.S. study
Objective: This study compared sociodemographic and clinical profiles of adult patients with lifetime DSM‐5‐defined anorexia nervosa (AN) categorized by age‐of‐onset using data from U.S. national sample of adults.Method: Study included 216 participants from Third National Epidemiological Survey Alcohol and Related Conditions (NESARC‐III) who met criteria for lifetime AN based on structured diagnostic interviews (AUDADIS‐5) with age‐of‐onset prior to age 25. Of the 216 participants, 30 were categorized as child‐onset (SE = 2.04; child‐onset), 39.6% (SE = 2.69; adolescent‐onset), and 48.6% (SE = 2.67; emerging‐adult). Child‐onset group reported more frequent adverse childhood experiences (ACEs), lowest BMI, longest episode‐duration, was least likely to attend college, and had highest rate of lifetime psychiatric comorbidity. Child‐onset group had earliest age of help‐seeking and were most likely to have been hospitalized. Group differences persisted in analyses adjusting for sociodemographic characteristics and duration of AN episode.Discussion: Our findings, based on a nationally representative sample of U.S. adults with lifetime diagnoses of AN, suggest that those with child‐onset had more severe AN, greater life difficulties, and greater lifetime psychiatric comorbidity. Findings emphasize the importance of earlier recognition and rapid referral to effective treatments.
- 29 December 2020
- Published by Wiley in International Journal of Eating Disorders
- Vol. 54 (3) , 326-335
Suicide attempts among people with eating disorders and adverse childhood experiences: Results from a nationally representative sample of adults
Objective: People with eating disorders (EDs) have elevated rates of suicide attempts. A need exists to identify factors that help predict which people with EDs might be at greater risk for suicidal behavior. Adverse childhood experiences (ACEs) are associated with both EDs and with suicide attempts. Thus, the current study examined whether having histories of ACEs and EDs augments lifetime risk for suicide attempts.Method: This study included 36,146 adult participants in the National Epidemiologic Survey on Alcohol and Related Conditions‐III who completed structured diagnostic interviews and answered questions regarding ACEs and suicide attempts. Weighted means, frequencies, and cross‐tabulations were computed for prevalence of ACEs and suicide attempts by ED diagnosis. Multiple logistic regression was used to compare risk of lifetime suicide attempts by ED diagnosis and ACE history.Results: Prevalence of ACEs among people with EDs was 54.1–67.8%. ACE history and ED diagnosis were associated with elevated odds of experiencing a lifetime suicide attempt (AORs = 4.64–6.45 and 3.20–4.06, respectively). There was no ACE history‐by‐ED interaction on risk of suicide attempt, regardless of forms of EDs.Discussion: ACEs are common among people with EDs and associated significantly with suicide attempts, but ACEs and EDs do not appear to interact to augment risk for suicide attempts. Considering ACE exposure in theoretical models of suicidal behavior in people with and without EDs and in suicide risk assessment and management with people with EDs may prove useful.
- 29 December 2020
- Published by Wiley in International Journal of Eating Disorders
- Vol. 54 (3) , 326-335
Suicide attempts among people with eating disorders and adverse childhood experiences: Results from a nationally representative sample of adults
Objective: People with eating disorders (EDs) have elevated rates of suicide attempts. A need exists to identify factors that help predict which people with EDs might be at greater risk for suicidal behavior. Adverse childhood experiences (ACEs) are associated with both EDs and with suicide attempts. Thus, the current study examined whether having histories of ACEs and EDs augments lifetime risk for suicide attempts.Method: This study included 36,146 adult participants in the National Epidemiologic Survey on Alcohol and Related Conditions‐III who completed structured diagnostic interviews and answered questions regarding ACEs and suicide attempts. Weighted means, frequencies, and cross‐tabulations were computed for prevalence of ACEs and suicide attempts by ED diagnosis. Multiple logistic regression was used to compare risk of lifetime suicide attempts by ED diagnosis and ACE history.Results: Prevalence of ACEs among people with EDs was 54.1–67.8%. ACE history and ED diagnosis were associated with elevated odds of experiencing a lifetime suicide attempt (AORs = 4.64–6.45 and 3.20–4.06, respectively). There was no ACE history‐by‐ED interaction on risk of suicide attempt, regardless of forms of EDs.Discussion: ACEs are common among people with EDs and associated significantly with suicide attempts, but ACEs and EDs do not appear to interact to augment risk for suicide attempts. Considering ACE exposure in theoretical models of suicidal behavior in people with and without EDs and in suicide risk assessment and management with people with EDs may prove useful.
- Open Access
- 1 October 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 38-39
Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19
- 1 October 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 99, 38-39
Open AccessClarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19